Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
about
MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinomaEpigenetics of lung cancerDose-dependent activation of putative oncogene SBSN by BORISSuprabasin is hypomethylated and associated with metastasis in salivary adenoid cystic carcinoma.Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma.Vaccine prevention of cancer: can endogenous antigens be targeted?Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.Derepression of Cancer/testis antigens in cancer is associated with distinct patterns of DNA hypomethylation.Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical studyExpression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.Suprabasin as a novel tumor endothelial cell marker.NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva.Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanomaEpigenetic regulation of the X-chromosomal macrosatellite repeat encoding for the cancer/testis gene CT47.Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.Cancer epigenetics: above and beyondCancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.Scavenger receptor class A member 5 (SCARA5) and suprabasin (SBSN) are hub genes of coexpression network modules associated with peripheral vein graft patency.Cancer/testis antigens and urological malignanciesThe significance of epigenetic alterations in lung carcinogenesis.Overexpression of Suprabasin is Associated with Proliferation and Tumorigenicity of Esophageal Squamous Cell Carcinoma.Epigenetic alteration of the purinergic type 7 receptor in salivary epithelial cells.Profiling cancer testis antigens in non-small-cell lung cancer.New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer.Epigenetic modulation of the muscarinic type 3 receptor in salivary epithelial cells.Expression of cancer/testis antigens in prostate cancer is associated with disease progression.NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.BORIS: a key regulator of cancer stemnessThe FENDRR/miR-214-3P/TET2 axis affects cell malignant activity via RASSF1A methylation in gastric cancer
P2860
Q21134039-59F7D53E-0CDA-4AED-AE31-BFD33BD60B7CQ26996766-9F3AE26E-A1F5-4A93-A4AB-3FC9AFC4D8BCQ28727517-2B8BAD54-EEF9-46BD-989F-D6B36921A3C8Q30424028-DFA5D746-8E65-47BC-9E42-FB4E4A308FBFQ30426166-8D698197-97CD-4C0B-AFED-8A836401034DQ33783609-5D085722-E893-4969-A908-BD0C8EE37CB7Q33957165-E567D9EB-0E87-4E30-858E-DE52BE769E7DQ34632716-722B4040-AC00-4785-9F99-E37D7C8DD246Q34839826-D4813B99-AE07-4F23-83D0-5474999CEA3AQ34870799-C948FEA6-7379-41E0-91AF-8EAC0C6036E0Q35052030-9CB89A13-E0E1-48A1-9CE1-F0F8D2EAD6BCQ35091263-2C1C458C-4114-4338-B298-EC39EE2FC724Q35091482-E90E7936-306C-4861-8C2F-76E75064E0CDQ35679712-C753C80D-8886-4AC0-BD9C-5E6964355680Q35829861-D316F557-82F4-45C0-8D6F-81AAD3BEB0DDQ35844494-3D934B46-43D1-4E98-BBA4-CF41E6C8A488Q35846167-46C29412-E30C-4F08-B617-1495943157A2Q36233760-26C211DD-82D8-4090-9FE9-9EA6263F8A0CQ36337004-0C2FA968-47B9-4BD9-BD83-F2545DA6F4A2Q36457427-2F64E937-5812-4AD6-966C-F8842927AF9CQ36602338-3EF82B64-FBE7-404C-A4BB-4071FF0F7618Q36641966-FA8A0781-8A17-409F-8259-DA389138E4F8Q37277266-7BB5E1C9-AFBA-4840-BE51-947AACB23C29Q38089480-AA0E8570-F562-4005-B67B-AEEFCA46E71BQ38414633-611EA39B-EAA4-43F6-9774-9EFD68FD8BAEQ38931086-A9DF8EC9-9E05-4700-9C05-2AC37C6C2349Q39687648-6B367384-2898-46D6-A81D-509B6AEBD2D8Q44264589-B9D15A45-ED56-4DEB-8585-ACE20330821DQ57482782-3FAA7F32-9757-4A53-8112-9E1B94D9DE8DQ58734058-A514A5CA-FF7E-47D6-8C28-69F361B858D3
P2860
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
@ast
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
@en
type
label
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
@ast
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
@en
prefLabel
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
@ast
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
@en
P2093
P2860
P1433
P1476
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC.
@en
P2093
Chad A Glazer
Ian M Smith
Joseph A Califano
Michael F Ochs
Shahnaz Begum
Sheetal Bhan
Steven S Chang
William Westra
Zubair Khan
P2860
P356
10.1371/JOURNAL.PONE.0008189
P407
P577
2009-12-04T00:00:00Z